Journal of Clinical Oncology, Vol 18, Issue 7
(April), 2000: 1474-1480
© 2000 American Society for Clinical Oncology
Post Hoc Economic Analysis of Temozolomide Versus Dacarbazine in the Treatment of Advanced Metastatic Melanoma
By Bruce E. Hillner,
Sanjiv Agarwala,
Mark R. Middleton
From the Department of Internal Medicine and the Massey Cancer Center, Medical College of Virginia Campus at Virginia Commonwealth University, Richmond, VA; University of Pittsburgh Cancer Institute, Pittsburgh, PA; Department of Medical Oncology, Christie Hospital National Health Services Trust, Manchester, United Kingdom.
Address reprint requests to Bruce E. Hillner, MD, Virginia Commonwealth University, Box 980170, Richmond, VA 23298-0170; email hillner{at}hsc.vcu.edu
PURPOSE: To determine the potential economic implications resulting from oral temozolomide (TEM) compared with intravenous (IV) dacarbazine (DTIC) for metastatic melanoma.
PATIENTS AND METHODS: We performed a cost-effectiveness (CE) analysis using hazard ratios (HRs) from the phase III (Schering I95–018) trial comparing TEM 200 mg/m2/d orally for 5 days every 28 days with DTIC 250 mg/m2/d IV for 5 days every 21 days. Sensitivity analyses assessed a range of TEM’s efficacy and costs, direct nonmedical costs, and the DTIC schedule.
RESULTS: The trial found an overall survival trend favoring TEM; median survival times of patients treated with DTIC and TEM were 6.4 and 7.7 months, respectively (HR = 1.18; 95% confidence interval [CI], 0.92 to 1.52; intention to treat, P = .20). The mean increase in survival of TEM over DTIC was 1.1 months. The projected average costs per patient were greater with TEM than DTIC ($6,902 v $3,697, respectively). The incremental CE ratio using TEM was $36,990 per life-year or $101 per day of life gained. The CE ratio’s 95% CI ranged from -$65,180 (DTIC is more effective) to $18,670 per year of life gained. The CE ratios decreased 50% if direct nonmedical costs were included and increased 50% if DTIC’s efficacy was unchanged if given as a single daily dosage. Sixty percent of simulations found TEM with a CE threshold of less than $50,000 per life-year gained.
CONCLUSION: Although the base-case efficacy of TEM compared with DTIC was not statistically significant, its associated incremental CE would be comparable with many interventions. TEM for metastatic melanoma illustrates the tension confronting providers choosing between similar agents that markedly differ in convenience and costs.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
J.-B. Wasserfallen, S. Ostermann, S. Leyvraz, and R. Stupp
Cost of temozolomide therapy and global care for recurrent malignant gliomas followed until death
Neuro-oncol,
April 1, 2005;
7(2):
189 - 195.
[Abstract]
[PDF]
|
|
|
|
|
|
|
N. B. Leighl, F. A. Shepherd, R. Kwong, R. L. Burkes, R. Feld, and P. J. Goodwin
Economic Analysis of the TAX 317 Trial: Docetaxel Versus Best Supportive Care as Second-Line Therapy of Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol.,
March 1, 2002;
20(5):
1344 - 1352.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stafford, A. Messori, S. Trippoli, P. Daealessandro, D. Di Giorgio, F. Tosolini, S. Hill, D. Henry, A. Mitchell, D. Rennie, et al.
Problems in Pharmacoeconomic Analyses
JAMA,
October 18, 2000;
284(15):
1922 - 1924.
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Trippoli, M. Vaiani, A. Messori, E. Tendi, and B. E. Hillner
Survival Gain in Cost-Effectiveness Studies
J. Clin. Oncol.,
September 18, 2000;
18(18):
3318 - 3318.
[Full Text]
[PDF]
|
|
|
|
